Current Approaches to the Management of Hemolytic Uremic Syndrome

  • Bernard S. Kaplan
  • Peter D. Thomson
Chapter
Part of the Developments in Nephrology book series (DINE, volume 7)

Abstract

As exemplified by our own experience (1,2), there has been a considerable improvement in the results of treatment of patients with hemolytic uremic syndrome (HUS). In Johannesburg in 1970, we studied 67 patients retrospectively and found an overall mortality rate of 34% (1). Further analysis revealed that 71% of severely affected cases died; none of the cases judged to be mildly affected died (Table 1). However, early treatment of severely affected cases with peritoneal dialysis reduced the mortality rate to 29%; this compared with an 80% mortality for severely affected patients who were not treated with dialysis. We, and others (3,4,5),have come to the conclusion that early institution of peritoneal dialysis was the most important therapeutic measure that could favourably influence the outcome of severely affected cases (Table 2).

Keywords

Aspirin Heparin Diarrhea Prostaglandin Meningitis 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Kaplan, B.S., Katz, J., Lurie, A., et al.: An analysis of the results of therapy in 67 cases of the hemolytic-uremic syndrome. J Pediatr 78: 420, 1981.Google Scholar
  2. 2.
    Kaplan, B.S., Thomson, P.D., and de Chadarevian, J-P.: The hemolytic-uremic syndrome. Pediatr Clin North Am 23: 761, 1976.PubMedGoogle Scholar
  3. 3.
    Gianantonio, C.A., Vitacco, M., Mendilaharzu, F., et al.: The hemolytic-uremic syndrome. Nephron 11: 174, 1973.PubMedCrossRefGoogle Scholar
  4. 4.
    Tune, B.M., Leavitt, T.J., and Gribble, T.J.: The hemolytic-uremic syndrome in California: A review of 12 non-heparinized cases with long-term follow-up. J Pediatr 82: 304, 1973.PubMedCrossRefGoogle Scholar
  5. 5.
    Date, A., Raghupathy, P., Jadhav, M., et al.: Outcome of the haemolytic-uraemic syndrome complicating bacillary dysentery. Annals of Tropical Paediatrics 2: 1, 1982.PubMedGoogle Scholar
  6. 6.
    Vitacco, M., Avalos, J.S., and Gianantonio, C.A.: Heparin therapy in the hemolytic-uremic syndrome. J Pediatr 83: 271, 1973.PubMedGoogle Scholar
  7. 7.
    Monnens, L., van Collenburg, J., de Jog, M., et al.: Treatment of the hemolytic-uremic syndrome. Helv Paediatr Acta 33: 321, 1978.PubMedGoogle Scholar
  8. 8.
    Proesmans, W., ki Muaka, B., Van Damme, B., et al.: The use of heparin in childhood hemolytic-uremic syndrome. In Remuzzi, G., Mecca, G., and de Gaetano, G. (eds.): Hemostasis,Prostaglandins and Renal Disease. New York, Raven Press, 1980.Google Scholar
  9. 9.
    Bergstein, J.M., Edson, J.R., and Michael, Jr., A.F.: Fibrinolytic treatment of the haemoly tic-iiraemic syndrome. Lancet 1: 448, 1972.PubMedCrossRefGoogle Scholar
  10. 10.
    Powell, H.R., and Ekert, H.: Streptokinase and anti-thrombotic therapy in the hemolytic-uremic syndrome. J Pediatr 84: 345, 1974.PubMedCrossRefGoogle Scholar
  11. 11.
    O’Regan, S., Chesney, R.W., Mongeau, J-G., et al.: Aspirin and dipyridamole therapy in the hemolytic-uremic syndrome. J Pediatr 97: 473, 1980.PubMedCrossRefGoogle Scholar
  12. 12.
    Jones, R.W.A., Morris, M.C., Maisey, M.N., et al.: Endarterial urokinase in childhood hemolytic uremic syndrome. Kidney Int 20: 723, 1981.PubMedCrossRefGoogle Scholar
  13. 13.
    Ekberg, M., Holmberg, L., and Denneberg, T.: Hemolytic uremic syndrome: results of treatment with hemodialysis. Acta Paediatr Scand 66: 693, 1977.PubMedCrossRefGoogle Scholar
  14. 14.
    Fong, J.S.C., de Chadarevian, J-P., and Kaplan, B.S.: Hemolytic- uremic syndrome: current concepts and management. Pediatr Clin N Amer 29: 835, 1982.Google Scholar
  15. 15.
    Remuzzi, G., Misiani, R., Marchesi, D., et al.: Haemolytic- uremic syndrome: Deficiency of plasma factor(s) regulating prostacyclin activity? Lancet 2: 871, 1978.PubMedCrossRefGoogle Scholar
  16. 16.
    Remuzzi, G., Misiani, R., Marchesi, D., et al.: Treatment of the hemolytic-uremic syndrome with plasma. Clin Nephrol 12: 279, 1979.PubMedGoogle Scholar
  17. 17.
    Karlsberg, R.P., Lacher, J.W., and Bartecchi, C.E.: Adult hemolytic uremic syndrome. Arch Intern Med 137: 1155, 1977.PubMedCrossRefGoogle Scholar
  18. 18.
    Hogewind, B.L., de la Riviere, G.B., van Es, L.A., et al.: Familial occurrence of the haemolytic uraemic syndrome. Acta Med Scand 207: 73, 1980.PubMedCrossRefGoogle Scholar
  19. 19.
    Segonds, A., Louradour, N., Sue, J.M., et al.: Postpartum hemolytic- uremic syndrome: A study of three cases with a review of the literature. Clin Nephrol 12: 229, 1979.PubMedGoogle Scholar
  20. 20.
    Habib, R., Levy, M., Gagnadoux, M-F., et al.: Prognosis of the hemolytic uremic syndrome in children. In Hamburger, J., et al. (eds.): Proceedings of the Necker Hospital. Chicago, Year Book Medical Publishers, 1982.Google Scholar
  21. 21.
    Thoenes, W., and John, H-D.: Endotheliotropic (hemolytic) nephroangiopathy and its various manifestation forms (thrombotic microangiopathy, primary malignant nephrosclerosis, hemolytic- uremic syndrome). Klin Wochenschr 58: 173, 1980.PubMedCrossRefGoogle Scholar
  22. 22.
    Trompeter, R.S., Schwartz, R., Chantler, C., et al.: Haemolytic- uraemic syndrome: An analysis of prognostic features. Personal communication.Google Scholar
  23. 23.
    Kaplan, B.S.: Hemolytic uremic syndrome with recurrent episodes: An important subset. Clin Nephrol 8: 495, 1977.PubMedGoogle Scholar
  24. 24.
    Remuzzi, G., Livio, M., Mecca, G., et al.: Prostacyclin and kidney disease: Focus on uremia and thrombotic microangiopathy. In Lewis, P.J., and O’Grady, J. (eds.): Clinical Pharmacology of Prostacyclin. New York, Raven Press, 1981.Google Scholar
  25. 25.
    Levin, M., Elkon, K.B., Buckle, A.M., et al.: An inhibitor of prostacyclin production in the plasma of some children with the hemolytic uremic syndrome and thrombotic thrombocytopenic purpura. Kidney Int 22: 583, 1982.Google Scholar
  26. 26.
    Beattie, T.J., Murphy, A.V., and Arneil, G.C.: Studies on prostaglandin metabolism in hemolytic-uremic syndrome. Int J Pediatr Nephrol 2: 130, 1981.Google Scholar
  27. 27.
    Remuzzi, G., Marchesi, D., Misiani, R., et al.: Familial deficiency of a plasma factor stimulating vascular prostacyclin activity. Thromb Res 16: 517, 1979.PubMedCrossRefGoogle Scholar
  28. Wiles, P.G., Solomon, L.R., Lawler, W., et al.: Inherited plasma factor deficiency in haemolytic-uraemic syndrome. The Lancet i: 1105, 1981.Google Scholar
  29. 29.
    Jorgensen, K.A., and Pedersen, R.S.: Familial deficiency of prostacyclin production stimulating factor in the hemolytic uremic syndrqme of childhood. Thromb Res 21: 311, 1981.PubMedCrossRefGoogle Scholar
  30. 30.
    Misiani, R., Appiani, A.C., Edefonti, A., et al.: Haemolytic uraemic syndrome: therapeutic effect of plasma infusion. Br Med J 285:1304,- 1982.Google Scholar
  31. 31.
    Denneberg, T., Friedberg, M., Holmberg, L., et al.: Combined plasmapheresis and hemodialysis treatment for severe hemolytic- uremic syndrome following Campylobacter colitis. Acta Paediatr Scand 71: 243, 1982.PubMedCrossRefGoogle Scholar
  32. 32.
    Beattie, T.J., Murphy, A.V., Willoughby, M.L.N., et al.: Plasmapheresis in the haemolytic-uraemic syndrome in children. Br Med J 282: 1667, 1981.CrossRefGoogle Scholar
  33. 33.
    Stuart, M.J., Spitzer, R.E., and Coppe, D.: Abnormal platelet and vascular prostaglandin synthesis in an infant with hemolytic uremic syndrome. Pediatr 71: 120, 1983.Google Scholar
  34. 34.
    Fong, J.S.C., and Kaplan, B.S.: Impairment of platelet aggregation in hemolytic uremic syndrome: Evidence for platelet “exhaustion”. Blood 60: 564, 1982.PubMedGoogle Scholar
  35. 35.
    O’Regan, S., Chesney, R.W., Kaplan, B.S., et al.: Red cell membrane abnormalities in the hemolytic-uremic syndrome. Clin Nephrol 15: 14, 1980.Google Scholar
  36. 36.
    Brandt, P., Jespersen, J., and Gregersen, G.: Post-partum haemolytic-uraemic syndrome treated with antithrombin-III. Nephron 27: 15, 1981.PubMedCrossRefGoogle Scholar
  37. 37.
    Moake, J.L., Rudy, C.K., Troll, J.H., et al.: Unusually large plasma factor VIII: Von Willebrand factor multimers in chronic relapsing thrombotic thrombocytopenic purpura..N Engl J Med 307: 1432, 1982.PubMedCrossRefGoogle Scholar
  38. 38.
    Kaplan, B.S., and Thomson, P.D.: Hyperuricemia in the hemolytic- uremic syndrome. Am J Dis Child 130: 854, 1976.PubMedGoogle Scholar
  39. 39.
    Bergstein, J.M., Kuederli, U., and Bang, N.U. Plasma inhibitor of glomerular fibrinolysis in the hemolytic-uremic syndrome. Am J Med 73: 322, 1982.PubMedCrossRefGoogle Scholar
  40. 40.
    Ibels, L.S., Alfrey, A.C., Haut, L., et al.: Preservation of function in experimental renal disease by dietary restriction of phosphate. N Engl J Med 298: 122, 1978.PubMedCrossRefGoogle Scholar
  41. 41.
    Karlinsky, M.L., Haut, L., Buddington, B., et al.: Preservation of renal function in experimental glomerulonephritis. Kidney Int 17: 293, 1980.PubMedCrossRefGoogle Scholar
  42. 42.
    Kaplan, B.S., Hebert, D., and Morrell, R-E: Acute renal failure induced by hyperphosphatemia in acute lymphoblastic leukemia. Canad Med Assoc J 124: 429, 1981.PubMedGoogle Scholar
  43. 43.
    de Chadarevian, J-P., and Kaplan, B.S.: The hemolytic uremic syndrome of childhood. In Rosenberg H.S. and Bolande R.P. (eds.): Perspectives in Pediatric Pathology, Vol. 4. Chicago, Year Book Medical Publishers, 1978.Google Scholar
  44. 44.
    Barre, P., Kaplan, B.S., de Chadarevian, J-P., et al.: Hemolytic uremic syndrome with hypocomplementemia, serum C3NeF, and glomerular deposits of C3. Arch Pathol Lab Med 101: 357, 1977.PubMedGoogle Scholar
  45. 45.
    de Chadarevian, J-P., Goodyer, P.R., and Kaplan, B.S.: Acute glomerulonephritis and hemolytic uremic syndrome. Canad Med Assoc J 123: 391, 1980.PubMedGoogle Scholar
  46. 46.
    Kaplan, B.S.: Hemolytic-uremic syndrome followed by idiopathic thrombocytopenic purpura. Int J Pediatr Nephrol 2: 97, 1981.PubMedGoogle Scholar

Copyright information

© Martinus Nijhoff Publishing, Boston 1984

Authors and Affiliations

  • Bernard S. Kaplan
  • Peter D. Thomson

There are no affiliations available

Personalised recommendations